Details for Patent: 9,125,908
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,125,908 protect, and when does it expire?
Patent 9,125,908 protects TRINTELLIX and is included in one NDA.
This patent has ninety patent family members in thirty-three countries.
Summary for Patent: 9,125,908
Title: | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment |
Abstract: | 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT.sub.3 and 5-HT.sub.1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients. ##STR00001## |
Inventor(s): | Bang-Andersen; Benny (Copenhagen S, DK), Mork; Arne (Malov, DK), Stensbol; Tine Bryan (Vaerlose, DK), Faldt; Andre (Ishoj, DK), Holm; Rene (Jyllinge, DK), de Diego; Heidi Lopez (Naerum, DK) |
Assignee: | H. Lundbeck A/S (Copenhagen-Valby, DK) |
Application Number: | 14/242,510 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,125,908 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,125,908
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-001 | Sep 30, 2013 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION | See Plans and Pricing | ||||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-002 | Sep 30, 2013 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION | See Plans and Pricing | ||||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-003 | Sep 30, 2013 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION | See Plans and Pricing | ||||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-004 | Sep 30, 2013 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,125,908
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Denmark | 2006 00824 | Jun 16, 2006 |
Denmark | 2006 01223 | Sep 22, 2006 |
Denmark | 2006 01384 | Oct 25, 2006 |
Denmark | 2007 00427 | Mar 20, 2007 |
International Family Members for US Patent 9,125,908
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 061481 | See Plans and Pricing | |||
Argentina | 065797 | See Plans and Pricing | |||
Austria | 495745 | See Plans and Pricing | |||
Austria | 540941 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |